GALT Galectin Therapeutics Inc

Galectin Therapeutics Inc is a clinical stage biopharmaceutical company. The Company is engaged in drug research and development to create new therapies for fibrotic disease and cancer.

$2.17
As of 04/13/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  03/05/2012
Outstanding shares:  57,156,030
Average volume:  1,250,625
Market cap:   $129,744,188
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    363225202
ISIN:        US3632252025
Sedol:      B7ZN8B9
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   2.73
PS ratio:   0.00
Return on equity:   -64.63%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy